Erwin Dreesen
Katholieke Universiteit Leuven
PharmacodynamicsPharmacokineticsInterquartile rangeInternal medicineAntibodyIntensive care medicineTumor necrosis factor alphaProspective cohort studyImmunologyVedolizumabInfliximabDosingInflammatory bowel diseaseMaintenance therapyUstekinumabCrohn's diseaseDrugTherapeutic drug monitoringUlcerative colitisPopulationAntifungal drugIn patientBiosimilarMedicineGastroenterologyPharmacology
Publications 88
#1Erwin Dreesen (Katholieke Universiteit Leuven)H-Index: 14
#1Marlies Oorts (Katholieke Universiteit Leuven)H-Index: 7
#2Pieter Van Brantegem (Katholieke Universiteit Leuven)H-Index: 3
Last. Pieter Annaert (Katholieke Universiteit Leuven)H-Index: 51
view all 9 authors...
Bosentan, a well-known cholestatic agent, was not identified as cholestatic at concentrations up to 200 µM based on the drug-induced cholestasis (DIC) index value, determined in a sandwich-cultured human hepatocyte (SCHH)-based DIC assay. To obtain further quantitative insights into the effects of bosentan on cellular bile salt handling by human hepatocytes, the present study determined the effect of 2.5-25 µM bosentan on endogenous bile salt levels and on the disposition of 10 µM chenodeoxychol...
#1Omar Elkayal (UMFCD: Carol Davila University of Medicine and Pharmacy)
#1Omar Elkayal (UMFCD: Carol Davila University of Medicine and Pharmacy)
Last. Erwin DreesenH-Index: 14
view all 9 authors...
BACKGROUND Posaconazole oral suspension emerged as a promising candidate for prophylaxis of invasive fungal infections in immunocompromised children. Its pharmacodynamic advantages include a broad-spectrum activity and a favorable safety profile; however, they are overshadowed by its large pharmacokinetic (PK) variability, which might cause subtherapeutic exposure. AIMS To develop a population (pop) PK model based on rich sampling data to better understand the PK of posaconazole oral suspension ...
1 CitationsSource
#1Sabrina De Winter (Katholieke Universiteit Leuven)H-Index: 8
#2Reinier M. van Hest (UvA: University of Amsterdam)H-Index: 6
Last. Peter Vanbrabant (Katholieke Universiteit Leuven)H-Index: 9
view all 12 authors...
There may be a difference between the determinants of amikacin exposure in emergency department (ED) versus intensive care (ICU) patients, and the peak amikacin concentration varies widely between patients. Moreover, when the first dose of antimicrobials is administered to septic patients admitted to the ED, fluid resuscitation and vasopressors have just been initiated. Nevertheless, population pharmacokinetic modelling data for amikacin in ED patients are unavailable. The aim of this study was ...
#1Zhigang Wang (Katholieke Universiteit Leuven)H-Index: 1
#2Bram Verstockt (Katholieke Universiteit Leuven)H-Index: 20
Last. Erwin Dreesen (Uppsala University)H-Index: 14
view all 7 authors...
Aims null In the UNITI endoscopy sub-study, only 17.4% of patients with Crohn's disease (CD) on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week (w)44. We aimed to evaluate the impact of alternative ustekinumab dosage regimens on endoscopic outcomes based on population pharmacokinetic-pharmacodynamic (popPK-PD) modeling and simulation analysis. null Methods null Real-world data were obtained from 83 patients with moderate-to-severe CD (95% biol...
#1Lore Vanderbeke (Katholieke Universiteit Leuven)H-Index: 7
#2P. Van Mol (Katholieke Universiteit Leuven)H-Index: 1
Last. Joost Wauters (Katholieke Universiteit Leuven)H-Index: 23
view all 55 authors...
The host immune response in symptomatic COVID-19 patients seems ineffective in clearing SARS-CoV-2, yet excessive in causing local tissue damage and hypercytokinemia. To elucidate the immunopathology underlying COVID-19 severity, cytokine profiling was performed in mild-moderate and critically-ill COVID-19 patients. Hypercytokinemia in COVID-19 differed from the IFN-γ-driven cytokine storm in macrophage activation syndrome, but was increased in critical versus mild-moderate COVID-19. Systems mod...
#1Laurens Liesenborghs (Institute of Tropical Medicine Antwerp)H-Index: 15
#2Isabel Spriet (Katholieke Universiteit Leuven)H-Index: 26
Last. Matthias M. Engelen (Katholieke Universiteit Leuven)H-Index: 3
view all 39 authors...
#1Jurij Hanzel (Ljubljana University Medical Centre)H-Index: 5
#2Erwin Dreesen (Uppsala University)H-Index: 14
Last. Ron A. A. MathôtH-Index: 32
view all 10 authors...
BACKGROUND Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. It is unclear how vedolizumab exposure is linked to endoscopic remission in Crohn disease (CD). We aimed to develop a pharmacokinetic-pharmacodynamic model linking vedolizumab exposure to endoscopic remission in CD. METHODS Data were obtained from the first 110 patients participating in a phase 4 prospective multicenter trial (LOVE-CD; identifier: NC...
#3Pieter Annaert (Katholieke Universiteit Leuven)H-Index: 51
#5Yves Debaveye (Katholieke Universiteit Leuven)H-Index: 12
Last. Isabel Spriet (Katholieke Universiteit Leuven)H-Index: 26
view all 7 authors...
Existing evidence is inconclusive whether meropenem dosing should be adjusted in patients receiving extracorporeal membrane oxygenation (ECMO). Therefore, the aim of this observational matched cohort study was to evaluate the effect of ECMO on pharmacokinetic (PK) variability and target attainment (TA) of meropenem. Patients admitted to the intensive care unit (ICU) simultaneously treated with meropenem and ECMO were eligible. Patients were matched 1:1, based on renal function and body weight, w...